The press release dropped June 1: Conscientia Health is "emerging as a pioneer in clinician-driven AI for mental healthcare." Founder Dr. Simbiat Adighije says the company's AI is "clinician-trained, clinician-approved, and clinician-supervised at every step." It also launched AI-powered virtual primary care in April to integrate mental and physical health through telehealth.
Good messaging. The question is whether there's a stock behind it.
There isn't. Conscientia Health is a private telepsychiatry practice - founded by Dr. Adighije, serving over 12,000 patients across 50 U.S. states and 16 countries. No ticker. No market cap. No earnings report you can run through a screener. The AI mental health market is growing fast - analysts value it between $1.3 billion and $2.7 billion in 2026, with most projections expecting 25% to 35% compound annual growth. But a market-size forecast doesn't give you investable exposure to a private company.
The question isn't whether Conscientia's story is compelling. It's whether the publicly traded names that actually give you exposure to this theme are holding up under real numbers - or whether the narrative is outpacing the fundamentals.
Let's look at the three mental-health-adjacent stocks where the data is transparent and the factor stack is visible.
Teladoc Health (TDOC): The AI-mental-health bellwether that's bleeding users
Teladoc is the closest public proxy to the "AI-powered mental health platform" thesis. It owns BetterHelp, the largest direct-to-consumer digital talk therapy brand in the U.S., and it reported Q1 2026 results on April 29. The numbers don't track with the AI enthusiasm.
Q1 2026 revenue came in at $613.8 million, down 2% year over year. BetterHelp - the consumer mental health engine - lost 9% of its paying users, falling to 361,000, and revenue dropped 9% to $218.4 million. The Integrated Care segment grew 2% to $395.4 million, barely offsetting the BetterHelp erosion. For full-year 2026, Teladoc guided revenue to $2.48–$2.58 billion and adjusted EBITDA... to $267–$306 million.
The stock is trading around $7.90 with a market cap near $1.37 billion, up roughly 20% since late January after Q4 2025 earnings beat. But that bounce is a relief rally on a stock that has fallen from its peak, not a fundamental turnaround. BetterHelp is shifting from a cash-pay model to insurance acceptance - a structural change that could stabilize user economics long-term, but it's also an admission that the direct-to-consumer model was leaking. Teladoc also faces Medicare telehealth coverage reductions starting in 2026, which removes a revenue tailwind.
In our book, this is a name that scores on market position but fails on the growth and momentum factors. If the AI narrative is supposed to be carrying the mental health sector, Teladoc is where you check the pulse first. It isn't beating.
COMPASS Pathways (CMPS): The psychedelic psychiatry play riding FDA momentum
COMPASS Pathways is not an AI mental health company. It's a clinical-stage biotech developing MDMA-assisted therapy for PTSD and psilocybin-assisted therapy for depression. But it sits on watchlists labeled "mental health innovation" because the endpoint is the same: scalable treatment for conditions where existing drugs underperform.
The stock has surged - up roughly 60% in the 30 days through late May 2026, with the market cap jumping from roughly $0.53 billion to between $1.65–$1.91 billion. It closed near $13.06, driven by positive Q1 2026 earnings and FDA milestone progress. There are no product revenue streams at scale; the company is pre-commercial, and its valuation is a bet on regulatory approval timing.
That's a different factor stack entirely. COMPASS scores on momentum - the recent move is undeniable - but it has no valuation anchor since it trades without revenue or earnings. It's a clinical-stage binary: approval expands the multiple, delay collapses it. If you're building a barbell, this is the speculative growth sleeve - not the dividend floor, not the cash-flow compounder. The AI mental health thesis has nothing to do with COMPASS. But the broader "novel mental health treatment" narrative drags it into the same search results.
Acadia Healthcare (ACHC): The revenue machine the narratives ignore
Acadia Healthcare operates acute inpatient psychiatric facilities, specialty treatment programs, and comprehensive behavioral health services. It's not AI. It's not telehealth. It's physical facilities treating acute behavioral health conditions - the infrastructure play in a sector everyone is trying to disrupt with apps.
Q1 2026 revenue was $828.8 million, up 7.6% year over year, with same-facility revenue up 7.3% and admissions growing 6.5%. That is actual revenue growth from actual patient volume in a business that generates real cash flow. The stock trades around $26 with a consensus Hold rating.
This is the name that scores on the factor stack when you strip away the narrative layer. Growth factor: revenue rising in the mid-single digits with admissions growing faster than revenue, which suggests pricing or utilization leverage. Profitability: actual earnings, not adjusted EBITDA guidance three quarters out. Momentum: flat to modest - the market hasn't rewarded it the way it rewarded COMPASS - but that's exactly the gap a factor screener looks for. A stock with fundamentals that are improving but a price that hasn't caught up is often more actionable than one that's already repriced the narrative.
The catch: Acadia is a bricks-and-mortar operator facing regulatory scrutiny in the behavioral health space, and its growth depends on admissions volume that can be sensitive to insurance coverage changes and state regulations. It's not a painless compounder. But it's a business with real financial data you can score.
What the factor stack says
The AI-in-mental-health narrative is real. The market is growing, the press releases keep coming, and the clinical need is undeniable. But narratives don't produce grades. Data does.
If you want exposure to the AI mental health theme through publicly traded stocks, Teladoc is your only pure proxy - and its BetterHelp segment is contracting, not accelerating. If you want innovation momentum in novel mental health treatments, COMPASS Pathways delivers that, but it's a binary biotech bet, not a factor compounder. If you want a behavioral health company with actual revenue growth, improving admissions, and a valuation that hasn't been bid up by narrative, Acadia Healthcare is where the numbers are.
Conscientia Health may be a pioneer. But until it files an S-1 and gives you a ticker, its "pioneer" status belongs in a press release, not a portfolio. The process doesn't grade what it can't measure.
What would change the setup? BetterHelp stabilizing or growing its paying user base would flip Teladoc from Hold to Buy. COMPASS getting FDA approval for its lead program would turn momentum into something durable. Acadia beating on admissions again while maintaining margins would narrow the gap between fundamentals and price. Watch those triggers, not the headlines.
